Refining processes for the co-development of genome-based therapeutics and companion diagnostic tests: workshop summary
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Format: | Elektronisch E-Book |
| Sprache: | English |
| Veröffentlicht: |
Washington, D.C.
The National Academies Press
[2014]
|
| Schlagworte: | |
| Online-Zugang: | FAW01 FAW02 Volltext |
| Beschreibung: | Title from PDF title page Description based on version viewed June 30, 2014 |
| Beschreibung: | 1 online resource (1 PDF file (xx, 82 pages)) illustrations |
| ISBN: | 0309298210 0309298229 9780309298216 9780309298223 |
Internformat
MARC
| LEADER | 00000nmm a2200000zc 4500 | ||
|---|---|---|---|
| 001 | BV043027005 | ||
| 003 | DE-604 | ||
| 005 | 00000000000000.0 | ||
| 007 | cr|uuu---uuuuu | ||
| 008 | 151120s2014 |||| o||u| ||||||eng d | ||
| 020 | |a 0309298210 |9 0-309-29821-0 | ||
| 020 | |a 0309298229 |9 0-309-29822-9 | ||
| 020 | |a 9780309298216 |9 978-0-309-29821-6 | ||
| 020 | |a 9780309298223 |9 978-0-309-29822-3 | ||
| 035 | |a (OCoLC)883365884 | ||
| 035 | |a (DE-599)BVBBV043027005 | ||
| 040 | |a DE-604 |b ger |e rda | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-1046 |a DE-1047 | ||
| 082 | 0 | |a 615.19 |2 23 | |
| 100 | 1 | |a Beachy, Sarah H. |e Verfasser |4 aut | |
| 245 | 1 | 0 | |a Refining processes for the co-development of genome-based therapeutics and companion diagnostic tests |b workshop summary |c Sarah H. Beachy, Samuel G. Johnson, Steve Olson, and Adam C. Berger, rapporteurs ; Roundtable on Translating Genomic-Based Research for Health, Board on Health Sciences Policy, Institute of Medicine of the National Academies |
| 264 | 1 | |a Washington, D.C. |b The National Academies Press |c [2014] | |
| 300 | |a 1 online resource (1 PDF file (xx, 82 pages)) |b illustrations | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b c |2 rdamedia | ||
| 338 | |b cr |2 rdacarrier | ||
| 500 | |a Title from PDF title page | ||
| 500 | |a Description based on version viewed June 30, 2014 | ||
| 505 | 8 | |a Many drug developers have examined new strategies for creating efficiencies in their development processes, including the adoption of genomics-based approaches. Genomic data can identify new drug targets for both common and rare diseases, can predict which patients are likely to respond to a specific treatment, and has the potential to significantly reduce the cost of clinical trials by reducing the number of patients that must be enrolled in order to demonstrate safety and efficacy. A key component of the approval of targeted therapeutics is the ability to identify the population of patients who will benefit from treatment, and this has largely hinged on the co-development and co-submission to the FDA of a companion diagnostic test.The co-development process, or the development of the test and drug for the simultaneous submission to FDA, has led to a major alteration in the way that drugs are being developed, with traditionally separate entities--pharmaceutical and diagnostic companies--now working in close collaboration. Refining Processes for the Co-Development of Genome-Based Therapeutics and Companion Diagnostic Tests is the summary of a workshop held by the Roundtable on Translating Genomic-Based Research for Health on February 27, 2013 to examine and discuss challenges and potential solutions for the codevelopment of targeted therapeutics and companion molecular tests for the prediction of drug response. Prior to the workshop, key stakeholders, including laboratory and medical professional societies, were individually asked to provide possible solutions to resolve the concerns raised about co-development of companion diagnostic tests and therapies. Workshop speakers were charged with addressing these solutions in their presentations by providing insight on (1) whether the proposed solutions address the problems described, (2) whether there are other solutions to propose, and (3) what steps could be taken to effectively implement the proposed solutions | |
| 650 | 4 | |a Drug Design / United States / Congresses | |
| 650 | 4 | |a Genetic Testing / United States / Congresses | |
| 650 | 4 | |a Genetic Therapy / United States / Congresses | |
| 650 | 7 | |a Drug development |2 fast | |
| 650 | 7 | |a Gene therapy |2 fast | |
| 650 | 7 | |a Human chromosome abnormalities / Diagnosis |2 fast | |
| 650 | 7 | |a Therapeutics |2 fast | |
| 650 | 7 | |a MEDICAL / Pharmacology |2 bisacsh | |
| 650 | 4 | |a Medizin | |
| 650 | 4 | |a Drug development |v Congresses | |
| 650 | 4 | |a Gene therapy |v Congresses | |
| 650 | 4 | |a Human chromosome abnormalities |x Diagnosis |v Congresses | |
| 650 | 4 | |a Therapeutics |v Congresses | |
| 651 | 4 | |a USA | |
| 655 | 7 | |0 (DE-588)1071861417 |a Konferenzschrift |2 gnd-content | |
| 700 | 1 | |a Johnson, Samuel G. |e Sonstige |4 oth | |
| 700 | 1 | |a Olson, Steve |d 1956- |e Sonstige |4 oth | |
| 700 | 1 | |a Berger, Adam C. |e Sonstige |4 oth | |
| 710 | 2 | |a Institute of Medicine (U.S.) |b Roundtable on Translating Genomic-Based Research for Health |e Sonstige |4 oth | |
| 710 | 2 | |a Refining Processes for the Co-Development of Genome-Based Therapeutics and Companion Diagnostic Tests (Workshop) <2013, Washington, D.C.> |e Sonstige |4 oth | |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |a Refining processes for the co-development of genome-based therapeutics and companion diagnostic tests : workshop summary |
| 856 | 4 | 0 | |u http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=867596 |x Aggregator |3 Volltext |
| 912 | |a ZDB-4-EBA | ||
| 999 | |a oai:aleph.bib-bvb.de:BVB01-028451659 | ||
| 966 | e | |u http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=867596 |l FAW01 |p ZDB-4-EBA |q FAW_PDA_EBA |x Aggregator |3 Volltext | |
| 966 | e | |u http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=867596 |l FAW02 |p ZDB-4-EBA |q FAW_PDA_EBA |x Aggregator |3 Volltext | |
Datensatz im Suchindex
| _version_ | 1804175380821573632 |
|---|---|
| any_adam_object | |
| author | Beachy, Sarah H. |
| author_facet | Beachy, Sarah H. |
| author_role | aut |
| author_sort | Beachy, Sarah H. |
| author_variant | s h b sh shb |
| building | Verbundindex |
| bvnumber | BV043027005 |
| collection | ZDB-4-EBA |
| contents | Many drug developers have examined new strategies for creating efficiencies in their development processes, including the adoption of genomics-based approaches. Genomic data can identify new drug targets for both common and rare diseases, can predict which patients are likely to respond to a specific treatment, and has the potential to significantly reduce the cost of clinical trials by reducing the number of patients that must be enrolled in order to demonstrate safety and efficacy. A key component of the approval of targeted therapeutics is the ability to identify the population of patients who will benefit from treatment, and this has largely hinged on the co-development and co-submission to the FDA of a companion diagnostic test.The co-development process, or the development of the test and drug for the simultaneous submission to FDA, has led to a major alteration in the way that drugs are being developed, with traditionally separate entities--pharmaceutical and diagnostic companies--now working in close collaboration. Refining Processes for the Co-Development of Genome-Based Therapeutics and Companion Diagnostic Tests is the summary of a workshop held by the Roundtable on Translating Genomic-Based Research for Health on February 27, 2013 to examine and discuss challenges and potential solutions for the codevelopment of targeted therapeutics and companion molecular tests for the prediction of drug response. Prior to the workshop, key stakeholders, including laboratory and medical professional societies, were individually asked to provide possible solutions to resolve the concerns raised about co-development of companion diagnostic tests and therapies. Workshop speakers were charged with addressing these solutions in their presentations by providing insight on (1) whether the proposed solutions address the problems described, (2) whether there are other solutions to propose, and (3) what steps could be taken to effectively implement the proposed solutions |
| ctrlnum | (OCoLC)883365884 (DE-599)BVBBV043027005 |
| dewey-full | 615.19 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 615 - Pharmacology and therapeutics |
| dewey-raw | 615.19 |
| dewey-search | 615.19 |
| dewey-sort | 3615.19 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>05155nmm a2200637zc 4500</leader><controlfield tag="001">BV043027005</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">151120s2014 |||| o||u| ||||||eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">0309298210</subfield><subfield code="9">0-309-29821-0</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">0309298229</subfield><subfield code="9">0-309-29822-9</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9780309298216</subfield><subfield code="9">978-0-309-29821-6</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9780309298223</subfield><subfield code="9">978-0-309-29822-3</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)883365884</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV043027005</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-1046</subfield><subfield code="a">DE-1047</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">615.19</subfield><subfield code="2">23</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Beachy, Sarah H.</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Refining processes for the co-development of genome-based therapeutics and companion diagnostic tests</subfield><subfield code="b">workshop summary</subfield><subfield code="c">Sarah H. Beachy, Samuel G. Johnson, Steve Olson, and Adam C. Berger, rapporteurs ; Roundtable on Translating Genomic-Based Research for Health, Board on Health Sciences Policy, Institute of Medicine of the National Academies</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Washington, D.C.</subfield><subfield code="b">The National Academies Press</subfield><subfield code="c">[2014]</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 online resource (1 PDF file (xx, 82 pages))</subfield><subfield code="b">illustrations</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Title from PDF title page</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Description based on version viewed June 30, 2014</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">Many drug developers have examined new strategies for creating efficiencies in their development processes, including the adoption of genomics-based approaches. Genomic data can identify new drug targets for both common and rare diseases, can predict which patients are likely to respond to a specific treatment, and has the potential to significantly reduce the cost of clinical trials by reducing the number of patients that must be enrolled in order to demonstrate safety and efficacy. A key component of the approval of targeted therapeutics is the ability to identify the population of patients who will benefit from treatment, and this has largely hinged on the co-development and co-submission to the FDA of a companion diagnostic test.The co-development process, or the development of the test and drug for the simultaneous submission to FDA, has led to a major alteration in the way that drugs are being developed, with traditionally separate entities--pharmaceutical and diagnostic companies--now working in close collaboration. Refining Processes for the Co-Development of Genome-Based Therapeutics and Companion Diagnostic Tests is the summary of a workshop held by the Roundtable on Translating Genomic-Based Research for Health on February 27, 2013 to examine and discuss challenges and potential solutions for the codevelopment of targeted therapeutics and companion molecular tests for the prediction of drug response. Prior to the workshop, key stakeholders, including laboratory and medical professional societies, were individually asked to provide possible solutions to resolve the concerns raised about co-development of companion diagnostic tests and therapies. Workshop speakers were charged with addressing these solutions in their presentations by providing insight on (1) whether the proposed solutions address the problems described, (2) whether there are other solutions to propose, and (3) what steps could be taken to effectively implement the proposed solutions</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drug Design / United States / Congresses</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Genetic Testing / United States / Congresses</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Genetic Therapy / United States / Congresses</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Drug development</subfield><subfield code="2">fast</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Gene therapy</subfield><subfield code="2">fast</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Human chromosome abnormalities / Diagnosis</subfield><subfield code="2">fast</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Therapeutics</subfield><subfield code="2">fast</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MEDICAL / Pharmacology</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Medizin</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drug development</subfield><subfield code="v">Congresses</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Gene therapy</subfield><subfield code="v">Congresses</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Human chromosome abnormalities</subfield><subfield code="x">Diagnosis</subfield><subfield code="v">Congresses</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Therapeutics</subfield><subfield code="v">Congresses</subfield></datafield><datafield tag="651" ind1=" " ind2="4"><subfield code="a">USA</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="0">(DE-588)1071861417</subfield><subfield code="a">Konferenzschrift</subfield><subfield code="2">gnd-content</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Johnson, Samuel G.</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Olson, Steve</subfield><subfield code="d">1956-</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Berger, Adam C.</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="710" ind1="2" ind2=" "><subfield code="a">Institute of Medicine (U.S.)</subfield><subfield code="b">Roundtable on Translating Genomic-Based Research for Health</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="710" ind1="2" ind2=" "><subfield code="a">Refining Processes for the Co-Development of Genome-Based Therapeutics and Companion Diagnostic Tests (Workshop) <2013, Washington, D.C.></subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="a">Refining processes for the co-development of genome-based therapeutics and companion diagnostic tests : workshop summary</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=867596</subfield><subfield code="x">Aggregator</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-4-EBA</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-028451659</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=867596</subfield><subfield code="l">FAW01</subfield><subfield code="p">ZDB-4-EBA</subfield><subfield code="q">FAW_PDA_EBA</subfield><subfield code="x">Aggregator</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=867596</subfield><subfield code="l">FAW02</subfield><subfield code="p">ZDB-4-EBA</subfield><subfield code="q">FAW_PDA_EBA</subfield><subfield code="x">Aggregator</subfield><subfield code="3">Volltext</subfield></datafield></record></collection> |
| genre | (DE-588)1071861417 Konferenzschrift gnd-content |
| genre_facet | Konferenzschrift |
| geographic | USA |
| geographic_facet | USA |
| id | DE-604.BV043027005 |
| illustrated | Illustrated |
| indexdate | 2024-07-10T07:15:22Z |
| institution | BVB |
| isbn | 0309298210 0309298229 9780309298216 9780309298223 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-028451659 |
| oclc_num | 883365884 |
| open_access_boolean | |
| owner | DE-1046 DE-1047 |
| owner_facet | DE-1046 DE-1047 |
| physical | 1 online resource (1 PDF file (xx, 82 pages)) illustrations |
| psigel | ZDB-4-EBA ZDB-4-EBA FAW_PDA_EBA |
| publishDate | 2014 |
| publishDateSearch | 2014 |
| publishDateSort | 2014 |
| publisher | The National Academies Press |
| record_format | marc |
| spelling | Beachy, Sarah H. Verfasser aut Refining processes for the co-development of genome-based therapeutics and companion diagnostic tests workshop summary Sarah H. Beachy, Samuel G. Johnson, Steve Olson, and Adam C. Berger, rapporteurs ; Roundtable on Translating Genomic-Based Research for Health, Board on Health Sciences Policy, Institute of Medicine of the National Academies Washington, D.C. The National Academies Press [2014] 1 online resource (1 PDF file (xx, 82 pages)) illustrations txt rdacontent c rdamedia cr rdacarrier Title from PDF title page Description based on version viewed June 30, 2014 Many drug developers have examined new strategies for creating efficiencies in their development processes, including the adoption of genomics-based approaches. Genomic data can identify new drug targets for both common and rare diseases, can predict which patients are likely to respond to a specific treatment, and has the potential to significantly reduce the cost of clinical trials by reducing the number of patients that must be enrolled in order to demonstrate safety and efficacy. A key component of the approval of targeted therapeutics is the ability to identify the population of patients who will benefit from treatment, and this has largely hinged on the co-development and co-submission to the FDA of a companion diagnostic test.The co-development process, or the development of the test and drug for the simultaneous submission to FDA, has led to a major alteration in the way that drugs are being developed, with traditionally separate entities--pharmaceutical and diagnostic companies--now working in close collaboration. Refining Processes for the Co-Development of Genome-Based Therapeutics and Companion Diagnostic Tests is the summary of a workshop held by the Roundtable on Translating Genomic-Based Research for Health on February 27, 2013 to examine and discuss challenges and potential solutions for the codevelopment of targeted therapeutics and companion molecular tests for the prediction of drug response. Prior to the workshop, key stakeholders, including laboratory and medical professional societies, were individually asked to provide possible solutions to resolve the concerns raised about co-development of companion diagnostic tests and therapies. Workshop speakers were charged with addressing these solutions in their presentations by providing insight on (1) whether the proposed solutions address the problems described, (2) whether there are other solutions to propose, and (3) what steps could be taken to effectively implement the proposed solutions Drug Design / United States / Congresses Genetic Testing / United States / Congresses Genetic Therapy / United States / Congresses Drug development fast Gene therapy fast Human chromosome abnormalities / Diagnosis fast Therapeutics fast MEDICAL / Pharmacology bisacsh Medizin Drug development Congresses Gene therapy Congresses Human chromosome abnormalities Diagnosis Congresses Therapeutics Congresses USA (DE-588)1071861417 Konferenzschrift gnd-content Johnson, Samuel G. Sonstige oth Olson, Steve 1956- Sonstige oth Berger, Adam C. Sonstige oth Institute of Medicine (U.S.) Roundtable on Translating Genomic-Based Research for Health Sonstige oth Refining Processes for the Co-Development of Genome-Based Therapeutics and Companion Diagnostic Tests (Workshop) <2013, Washington, D.C.> Sonstige oth Erscheint auch als Druck-Ausgabe Refining processes for the co-development of genome-based therapeutics and companion diagnostic tests : workshop summary http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=867596 Aggregator Volltext |
| spellingShingle | Beachy, Sarah H. Refining processes for the co-development of genome-based therapeutics and companion diagnostic tests workshop summary Many drug developers have examined new strategies for creating efficiencies in their development processes, including the adoption of genomics-based approaches. Genomic data can identify new drug targets for both common and rare diseases, can predict which patients are likely to respond to a specific treatment, and has the potential to significantly reduce the cost of clinical trials by reducing the number of patients that must be enrolled in order to demonstrate safety and efficacy. A key component of the approval of targeted therapeutics is the ability to identify the population of patients who will benefit from treatment, and this has largely hinged on the co-development and co-submission to the FDA of a companion diagnostic test.The co-development process, or the development of the test and drug for the simultaneous submission to FDA, has led to a major alteration in the way that drugs are being developed, with traditionally separate entities--pharmaceutical and diagnostic companies--now working in close collaboration. Refining Processes for the Co-Development of Genome-Based Therapeutics and Companion Diagnostic Tests is the summary of a workshop held by the Roundtable on Translating Genomic-Based Research for Health on February 27, 2013 to examine and discuss challenges and potential solutions for the codevelopment of targeted therapeutics and companion molecular tests for the prediction of drug response. Prior to the workshop, key stakeholders, including laboratory and medical professional societies, were individually asked to provide possible solutions to resolve the concerns raised about co-development of companion diagnostic tests and therapies. Workshop speakers were charged with addressing these solutions in their presentations by providing insight on (1) whether the proposed solutions address the problems described, (2) whether there are other solutions to propose, and (3) what steps could be taken to effectively implement the proposed solutions Drug Design / United States / Congresses Genetic Testing / United States / Congresses Genetic Therapy / United States / Congresses Drug development fast Gene therapy fast Human chromosome abnormalities / Diagnosis fast Therapeutics fast MEDICAL / Pharmacology bisacsh Medizin Drug development Congresses Gene therapy Congresses Human chromosome abnormalities Diagnosis Congresses Therapeutics Congresses |
| subject_GND | (DE-588)1071861417 |
| title | Refining processes for the co-development of genome-based therapeutics and companion diagnostic tests workshop summary |
| title_auth | Refining processes for the co-development of genome-based therapeutics and companion diagnostic tests workshop summary |
| title_exact_search | Refining processes for the co-development of genome-based therapeutics and companion diagnostic tests workshop summary |
| title_full | Refining processes for the co-development of genome-based therapeutics and companion diagnostic tests workshop summary Sarah H. Beachy, Samuel G. Johnson, Steve Olson, and Adam C. Berger, rapporteurs ; Roundtable on Translating Genomic-Based Research for Health, Board on Health Sciences Policy, Institute of Medicine of the National Academies |
| title_fullStr | Refining processes for the co-development of genome-based therapeutics and companion diagnostic tests workshop summary Sarah H. Beachy, Samuel G. Johnson, Steve Olson, and Adam C. Berger, rapporteurs ; Roundtable on Translating Genomic-Based Research for Health, Board on Health Sciences Policy, Institute of Medicine of the National Academies |
| title_full_unstemmed | Refining processes for the co-development of genome-based therapeutics and companion diagnostic tests workshop summary Sarah H. Beachy, Samuel G. Johnson, Steve Olson, and Adam C. Berger, rapporteurs ; Roundtable on Translating Genomic-Based Research for Health, Board on Health Sciences Policy, Institute of Medicine of the National Academies |
| title_short | Refining processes for the co-development of genome-based therapeutics and companion diagnostic tests |
| title_sort | refining processes for the co development of genome based therapeutics and companion diagnostic tests workshop summary |
| title_sub | workshop summary |
| topic | Drug Design / United States / Congresses Genetic Testing / United States / Congresses Genetic Therapy / United States / Congresses Drug development fast Gene therapy fast Human chromosome abnormalities / Diagnosis fast Therapeutics fast MEDICAL / Pharmacology bisacsh Medizin Drug development Congresses Gene therapy Congresses Human chromosome abnormalities Diagnosis Congresses Therapeutics Congresses |
| topic_facet | Drug Design / United States / Congresses Genetic Testing / United States / Congresses Genetic Therapy / United States / Congresses Drug development Gene therapy Human chromosome abnormalities / Diagnosis Therapeutics MEDICAL / Pharmacology Medizin Drug development Congresses Gene therapy Congresses Human chromosome abnormalities Diagnosis Congresses Therapeutics Congresses USA Konferenzschrift |
| url | http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=867596 |
| work_keys_str_mv | AT beachysarahh refiningprocessesforthecodevelopmentofgenomebasedtherapeuticsandcompaniondiagnostictestsworkshopsummary AT johnsonsamuelg refiningprocessesforthecodevelopmentofgenomebasedtherapeuticsandcompaniondiagnostictestsworkshopsummary AT olsonsteve refiningprocessesforthecodevelopmentofgenomebasedtherapeuticsandcompaniondiagnostictestsworkshopsummary AT bergeradamc refiningprocessesforthecodevelopmentofgenomebasedtherapeuticsandcompaniondiagnostictestsworkshopsummary AT instituteofmedicineusroundtableontranslatinggenomicbasedresearchforhealth refiningprocessesforthecodevelopmentofgenomebasedtherapeuticsandcompaniondiagnostictestsworkshopsummary AT refiningprocessesforthecodevelopmentofgenomebasedtherapeuticsandcompaniondiagnostictestsworkshop2013washingtondc refiningprocessesforthecodevelopmentofgenomebasedtherapeuticsandcompaniondiagnostictestsworkshopsummary |